Reducing the global burden of HTLV-1 infection: An agenda for research and action

[en] Even though an estimated 10e20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

Disciplines :

Oncology

Author, co-author :

Willems, Luc ; Université de Liège > Agronomie, Bio-ingénierie et Chimie (AgroBioChem) > Biologie cell. et moléc.

Hasegawa, Hideki

Accolla, Roberto

Bangham, Charles

Bazarbachi, Ali

Bertazzoni, Umberto

Barbara de Freitas Carneiro-Proietti, Anna

Cheng, Hua

Chieco-Bianchi, Luigi

Ciminale, Vincenzo

More authors (20 more)

Language :

English

Title :

Reducing the global burden of HTLV-1 infection: An agenda for research and action

Publication date :

11 November 2016

Journal title :

Antiviral Research

ISSN :

0166-3542

Publisher :

Elsevier, Amsterdam, Netherlands

Volume :

137

Issue :

2017

Pages :

41-48

Peer reviewed :

Peer Reviewed verified by ORBi

Name of the research project :

the Interuniversity Attraction Poles (IAP)
Program “Virus-host interplay at the early phases of infection” BELVIR initiated by the Belgian Science Policy Office
AgricultureIsLife

Funders :

F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Télévie [BE]
BELSPO - Politique scientifique fédérale [BE]
Belgian Foundation Against Cancer [BE]
CAC - Centre anticancéreux près l'Université de Liège asbl [BE]
Fonds Léon Fredericq [BE]
ULiège. GxABT - Liège Université. Gembloux Agro-Bio Tech [BE]
ULg FSR - Université de Liège. Fonds spéciaux pour la recherche [BE]

Funding text :

The “Plan Cancer” of the Service Public Federal

Available on ORBi :

since 30 January 2017

Statistics

Number of views

56 (10 by ULiège)

Number of downloads

3 (3 by ULiège)

More statistics

Scopus citations^®

102

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Asquith, B., Bangham, C.R.M., How does HTLV-I persist despite a strong cell-mediated immune response?. Trends Immunol. 29 (2008), 4–11, 10.1016/j.it.2007.09.006.
Bangham, C.R.M., Araujo, A., Yamano, Y., Taylor, G.P., HTLV-1-associated myelopathy/tropical spastic paraparesis. Nat. Rev. Dis. Prim., 1, 2015, 15012, 10.1038/nrdp.2015.12.
Bazarbachi, A., Plumelle, Y., Ramos, J.C., Tortevoye, P., Otrock, Z., Taylor, G., Gessain, A., Harrington, W., Panelatti, G., Hermine, O., Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 28 (2010), 4177–4183, 10.1200/JCO.2010.28.0669.
Boxus, M., Twizere, J.C., Legros, S., Kettmann, R., Willems, L., Interaction of HTLV-1 Tax with minichromosome maintenance proteins accelerates the replication timing program. Blood 119 (2012), 151–160, 10.1182/blood-2011-05-356790.
Calattini, S., Chevalier, S.A., Duprez, R., Afonso, P., Froment, A., Gessain, A., Mahieux, R., Human T-cell lymphotropic virus type 3: complete nucleotide sequence and characterization of the human tax3 protein. J. Virol. 80 (2006), 9876–9888, 10.1128/JVI.00799-06.
de Brogniez, A., Bouzar, A.B., Jacques, J.-R., Cosse, J.-P., Gillet, N., Callebaut, I., Reichert, M., Willems, L., Mutation of a single envelope N-Linked glycosylation site enhances the pathogenicity of bovine leukemia virus. J. Virol. 89 (2015), 8945–8956, 10.1128/JVI.00261-15.
Enose-Akahata, Y., Caruso, B., Haner, B., Charlip, E., Nair, G., Massoud, R., Billioux, B.J., Ohayon, J., Switzer, W.M., Jacobson, S., Development of neurologic diseases in a patient with primate T lymphotropic virus type 1 (PTLV-1). Retrovirology, 13, 2016, 56, 10.1186/s12977-016-0290-9.
Filippone, C., Betsem, E., Tortevoye, P., Cassar, O., Bassot, S., Froment, A., Fontanet, A., Gessain, A., A severe bite from a nonhuman primate is a major risk factor for HTLV-1 infection in hunters from central Africa. Clin. Infect. Dis., 2015, 1–10, 10.1093/cid/civ145.
Gabet, A.-S., Mortreux, F., Talarmin, A., Plumelle, Y., Leclercq, I., Leroy, A., Gessain, A., Clity, E., Joubert, M., Wattel, E., High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene 19 (2000), 4954–4960, 10.1038/sj.onc.1203870.
Gessain, A., Cassar, O., Epidemiological aspects and world distribution of HTLV-1 infection. Front. Microbiol. 3 (2012), 1–23, 10.3389/fmicb.2012.00388.
Ghez, D., Lepelletier, Y., Jones, K.S., Pique, C., Hermine, O., Current concepts regarding the HTLV-1 receptor complex. Retrovirology, 7, 2010, 99, 10.1186/1742-4690-7-99.
Gillet, N.A., Malani, N., Melamed, A., Gormley, N., Carter, R., Bentley, D., Bushman, F.D., Taylor, G.P., Bangham, C.R.M., Dc, W., Berry, C., The host genomic environment of the provirus determines the abundance of HTLV-1 − infected T-cell clones. Blood 117 (2011), 3113–3122, 10.1182/blood-2010-10-312926.
Gillet, N.A., Gutiérrez, G., Rodriguez, S.M., de Brogniez, A., Renotte, N., Alvarez, I., Trono, K., Willems, L., Massive depletion of bovine leukemia virus proviral clones located in genomic transcriptionally active sites during primary infection. PLoS Pathog., 9, 2013, e1003687, 10.1371/journal.ppat.1003687.
Gonçalves, D.U., Proietti, F.A., Ribas, J.G.R., Araujo, M.G., Pinheiro, S.R., Guedes, A.C., Carneiro-Proietti, A.B.F., Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin. Microbiol. Rev. 23 (2010), 577–589, 10.1128/CMR.00063-09.
Gutiérrez, G., Rodríguez, S.M., De Brogniez, A., Gillet, N., Golime, R., Burny, A., Jaworski, J.P., Alvarez, I., Vagnoni, L., Trono, K., Willems, L., Vaccination against δ-retroviruses: the bovine leukemia virus paradigm. Viruses 6 (2014), 2416–2427, 10.3390/v6062416.
Kataoka, K., Nagata, Y., Kitanaka, A., Shiraishi, Y., Shimamura, T., Yasunaga, J., Totoki, Y., Chiba, K., Sato-Otsubo, A., Nagae, G., Ishii, R., Muto, S., Kotani, S., Watatani, Y., Takeda, J., Sanada, M., Tanaka, H., Suzuki, H., Sato, Y., Shiozawa, Y., Yoshizato, T., Yoshida, K., Makishima, H., Iwanaga, M., Ma, G., Nosaka, K., Hishizawa, M., Itonaga, H., Imaizumi, Y., Munakata, W., Ogasawara, H., Sato, T., Sasai, K., Muramoto, K., Penova, M., Kawaguchi, T., Nakamura, H., Hama, N., Shide, K., Kubuki, Y., Hidaka, T., Kameda, T., Nakamaki, T., Ishiyama, K., Miyawaki, S., Yoon, S.-S., Tobinai, K., Miyazaki, Y., Takaori-Kondo, A., Matsuda, F., Takeuchi, K., Nureki, O., Aburatani, H., Watanabe, T., Shibata, T., Matsuoka, M., Miyano, S., Shimoda, K., Ogawa, S., Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat. Genet., 2015, 10.1038/ng.3415.
Kato, K., Akashi, K., Recent advances in therapeutic approaches for adult T-cell leukemia/lymphoma. Viruses 7 (2015), 6604–6612, 10.3390/v7122960.
Kchour, G., Rezaee, R., Farid, R., Ghantous, A., Rafatpanah, H., Tarhini, M., Kooshyar, M.M., El Hajj, H., Berry, F., Mortada, M., Nasser, R., Shirdel, A., Dassouki, Z., Ezzedine, M., Rahimi, H., Ghavamzadeh, A., de The, H., Hermine, O., Mahmoudi, M., Bazarbachi, A., The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology, 10, 2013, 91, 10.1186/1742-4690-10-91.
Martin, F., Taylor, G.P., Jacobson, S., Inflammatory manifestations of HTLV-1 and their therapeutic options. Expert Rev. Clin. Immunol. 10 (2014), 1531–1546, 10.1586/1744666X.2014.966690.
Matsuoka, M., Jeang, K.-T., Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer 7 (2007), 270–280, 10.1038/nrc2111.
McSweegan, E., Weaver, S.C., Lecuit, M., Frieman, M., Morrison, T.E., Hrynkow, S., The global virus Network: challenging chikungunya. Antivir. Res. 120 (2015), 147–152, 10.1016/j.antiviral.2015.06.003.
Murphy, E.L., Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): implications for blood transfusion safety. Transfus. Clin. Biol. J. Société Fr. Transfus. Sang. 23 (2016), 13–19, 10.1016/j.tracli.2015.12.001.
Olindo, S., Belrose, G., Gillet, N., Rodriguez, S., Boxus, M., Verlaeten, O., Asquith, B., Bangham, C., Signate, A., Smadja, D., Lezin, A., Cesaire, R., Willems, L., Brief report Safety of long-term treatment of HAM/TSP patients with valproic acid. Blood 118 (2011), 6306–6309, 10.1182/blood-2011-04-349910.
Pique, C., Jones, K.S., Pathways of cell-cell transmission of HTLV-1. Front. Microbiol. 3 (2012), 1–14, 10.3389/fmicb.2012.00378.
Richard, L., Mouinga-Ondémé, A., Betsem, E., Filippone, C., Nerrienet, E., Kazanji, M., Gessain, A., Zoonotic transmission of two new strains of human T-lymphotropic virus type 4 in hunters bitten by a Gorilla in central Africa. Clin. Infect. Dis., 2016, 1–4, 10.1093/cid/ciw389 ahead of p.
Sibon, D., Gabet, A.S., Zandecki, M., Pinatel, C., Thête, J., Delfau-Larue, M.H., Rabaaoui, S., Gessain, A., Gout, O., Jacobson, S., Mortreux, F., Wattel, E., HTLV-1 propels untransformed CD4+ lymphocytes into the cell cycle while protecting CD8+ cells from death. J. Clin. Investig. 116 (2006), 974–983, 10.1172/JCI27198.
Suehiro, Y., Hasegawa, A., Iino, T., Sasada, A., Watanabe, N., Matsuoka, M., Takamori, A., Tanosaki, R., Utsunomiya, A., Choi, I., Fukuda, T., Miura, O., Takaishi, S., Teshima, T., Akashi, K., Kannagi, M., Uike, N., Okamura, J., Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br. J. Haematol. 169 (2015), 356–367, 10.1111/bjh.13302.
Tsukasaki, K., Hermine, O., Bazarbachi, A., Ratner, L., Ramos, J.C., Harrington, W., O'Mahony, D., Janik, J.E., Bittencourt, A.L., Taylor, G.P., Yamaguchi, K., Utsunomiya, A., Tobinai, K., Watanabe, T., Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J. Clin. Oncol. 27 (2009), 453–459, 10.1200/JCO.2008.18.2428.
Tsukasaki, K., Tobinai, K., Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research. Clin. Cancer Res. 20 (2014), 5217–5225, 10.1158/1078-0432.CCR-14-0572.
Yamagishi, M., Nakano, K., Miyake, A., Yamochi, T., Kagami, Y., Tsutsumi, A., Matsuda, Y., Sato-Otsubo, A., Muto, S., Utsunomiya, A., Yamaguchi, K., Uchimaru, K., Ogawa, S., Watanabe, T., Polycomb-mediated loss of miR-31 activates nik-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell 21 (2012), 121–135, 10.1016/j.ccr.2011.12.015.